¼¼°èÀÇ À§ Àü±â Àڱر⠽ÃÀå
Gastric Electrical Stimulators
»óǰÄÚµå : 1757607
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 368 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,009,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,027,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ À§ Àü±â Àڱر⠽ÃÀåÀº 2030³â±îÁö 3¾ï 5,220¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 5,810¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ À§ Àü±â Àڱر⠽ÃÀåÀº 2024-2030³â¿¡ CAGR 5.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 3¾ï 5,220¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ °íÁÖÆÄ À¯ÇüÀº CAGR 6.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 2,570¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀúÁÖÆÄ À¯Çü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7,030¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À§ Àü±â Àڱر⠽ÃÀåÀº 2024³â¿¡ 7,030¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 7,120¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.5%¿Í 5.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ "À§ Àü±â Àڱرâ" ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

³­Ä¡¼º À§ºÎÀü ¸¶ºñ °ü¸®¿¡¼­ À§ Àü±â ÀڱرⰡ ºÎ»óÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

À§ Àü±â Àڱرâ(GES)´Â ¾à¹° ÀúÇ×¼º ¸¸¼º À§ºÎÀü ¸¶ºñ(±â°èÀû Æó¼â ¾øÀÌ À§ ¹èÃâ Áö¿¬À» Ư¡À¸·Î ÇÏ´Â Áúȯ)¸¦ ¾Î°í Àִ ȯÀڵ鿡°Ô Áß¿äÇÑ Ä¡·á ¿É¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚ¿Í Æ¯¹ß¼º ȯÀÚ ¸ðµÎ¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â À§¸¶ºñ´Â ¸Þ½º²¨¿ò, ±¸Åä, º¹ºÎ ÆØ¸¸°¨, º¹Åë µîÀÇ Áõ»óÀ¸·Î ÀÎÇØ »îÀÇ ÁúÀ» ½É°¢ÇÏ°Ô ÀúÇϽÃŵ´Ï´Ù. GES´Â ½ÄÀÌ¿ä¹ýÀ̳ª ¾à¹° Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ȯÀÚµéÀ» À§ÇØ À§ ÆòȰ±Ù¿¡ °æ¹ÌÇÑ Àü±â ÆÞ½º¸¦ º¸³» ¿îµ¿ ±â´ÉÀ» Çâ»ó½Ã۰í Áõ»óÀ» ¿ÏÈ­ÇÏ´Â ÃÖ¼Òħ½ÀÀûÀ̰í Àå±âÀûÀÎ ÁßÀ縦 Á¦°øÇÕ´Ï´Ù. ȯÀÚ Áý´Ü¿¡¼­ Áõ»óÀ» Å©°Ô ¿ÏÈ­½ÃÄÑ ÀÓ»óÀûÀ¸·Î ²ÙÁØÈ÷ ¼ö¿ëµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ´ç´¢º´ ȯÀÚµé »çÀÌ¿¡¼­ À§¸¶ºñ¿¡ ´ëÇÑ Àνİú Áø´ÜÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àü ¼¼°è ¼ÒÈ­±â³»°ú ¹× ¿Ü°ú Áø·á¿¡¼­ GES ÀÓÇöõÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô ±â±âÀÇ ¼º´É°ú ȯÀÚ ¿¹Èĸ¦ °³¼±Çϰí Àִ°¡?

GES ÀåºñÀÇ ÁøÈ­´Â »ýü ÀüÀÚ ÀÇÇÐ, ¹èÅ͸® ±â¼ú, Á¤¹Ð ÇÁ·Î±×·¡¹ÖÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÃֽŠÀڱرâ´Â ¹èÅ͸® ¼ö¸íÀÌ ±æ°í ÇÁ·Î±×·¡¹Ö °¡´ÉÇÑ ÀÚ±Ø ÆÄ¶ó¹ÌÅ͸¦ °®Ãá ¼ÒÇü À̽ÄÇü ÆÞ½º ¹ß»ý±â¸¦ Ư¡À¸·Î Çϸç, Àǻ簡 °³º° ȯÀÚÀÇ ¹ÝÀÀ¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÃÖ±Ù¿¡´Â ¹«¼± ¿ø°Ý ÃøÁ¤ÀÌ °¡´ÉÇÑ ½Ã½ºÅÛµµ Ãâ½ÃµÇ¾î ºñħ½ÀÀû Á¶Á¤ ¹× ¿ø°Ý ¸ð´ÏÅ͸µÀÌ °¡´ÉÇÕ´Ï´Ù. ¶ÇÇÑ ¸®µå ¼³°è ¹× ÀåÂø ±â¼úÀÇ °³¼±À¸·Î ±â±âÀÇ È¿À²¼ºÀÌ Çâ»óµÇ¾î ½Ã¼ú·Î ÀÎÇÑ ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. À§·ÎºÎÅÍÀÇ Çǵå¹é¿¡ µû¶ó ÀÚ±ØÀ» µ¿ÀûÀ¸·Î Á¶ÀýÇÒ ¼ö ÀÖ´Â Æó¼â ·çÇÁ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿¬±¸µµ ÁøÇà ÁßÀ¸·Î, º¸´Ù °³ÀÎÈ­µÇ°í È¿À²ÀûÀÎ Áõ»ó Á¶ÀýÀÇ °¡´É¼ºÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸¿¡¼­´Â ºñ¸¸, ±â´É¼º ¼ÒÈ­ºÒ·®Áõ, ¸¸¼º ¸Þ½º²¨¿ò ÁõÈıº µî À§ºÎÀü¸¶ºñ ÀÌ¿ÜÀÇ Áõ»ó¿¡ ´ëÇÑ GESÀÇ »ç¿ëÀÌ °ËÅäµÇ°í ÀÖÀ¸¸ç, ÀÓ»ó Àû¿ëÀÇ ÆøÀÌ ³Ð¾îÁú °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû, Ä¡·áÀû ¹ßÀüÀ¸·Î GES¿¡ ´ëÇÑ ÀÇ»çµéÀÇ ½Å·Ú°¡ ³ô¾ÆÁö¸é¼­ ´ëÇк´¿ø, Áö¿ªº´¿øÀ» ¸··ÐÇϰí GESÀÇ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

º¸Çè »óȯ, ÀÓ»ó °¡À̵å¶óÀÎ, Áúº´ ºÎ´ãÀº ½ÃÀå È®´ë¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?

À§ Àü±âÀڱرâÀÇ Ã¤ÅÃÀº ÀǷẸÇè, ÁøÈ­ÇÏ´Â Ä¡·á ÇÁ·ÎÅäÄÝ, À§ºÎÀü ¸¶ºñ À¯º´·ü Áõ°¡¿Í ¹ÐÁ¢ÇÏ°Ô ¿¬°üµÇ¾î ÀÖ½À´Ï´Ù. ¹Ì±¹°ú °°ÀÌ Medicare¿Í ¸¹Àº ¹Î°£ º¸Çè»ç°¡ ƯÁ¤ ÀûÀÀÁõ¿¡ ´ëÇØ GES¸¦ º¸ÇèÀ¸·Î º¸ÀåÇÏ´Â ±¹°¡¿¡¼­´Â GES¿¡ ´ëÇÑ Á¢±Ù À庮ÀÌ ÇöÀúÈ÷ ³·½À´Ï´Ù. µ¿½Ã¿¡, ³­Ä¡¼º À§¸¶ºñ ȯÀڵ鿡°Ô GES¸¦ È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î ÀÎÁ¤ÇÏ´Â ÀÓ»ó °¡À̵å¶óÀÎÀÌ ´Ã¾î³ª¸é¼­ Ä¡·á °æ·Î¿¡¼­ GESÀÇ ¿ªÇÒÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ´ç´¢º´, ƯÈ÷ 2Çü ´ç´¢º´ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ç´¢º´¼º À§ºÎÀü¸¶ºñ ¹ß»ý·üÀÌ ±Þ°ÝÈ÷ Áõ°¡ÇÏ¿© GES À̽ļúÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, À§¹èÃâ ½ÅÆ¼±×·¡ÇÇ¿Í °°Àº Áø´Ü ÅøÀÇ °³¼±Àº Àǻ簡 GES¿¡ ÀûÇÕÇÑ È¯ÀÚ¸¦ Á¶±â¿¡ ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. °³¹ßµµ»ó±¹¿¡¼­´Â °í±Þ ¼ö¼úÀû °³ÀÔ¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÌ°í ºñ¿ëÀûÀÎ Á¦¾àÀÌ ¿©ÀüÈ÷ ¹®Á¦ÀÌÁö¸¸, ¼ÒÈ­±â ÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ È®´ë¿Í ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó »õ·Î¿î Áö¿ª ½ÃÀåÀÌ °³¹ßµÇ±â ½ÃÀÛÇß½À´Ï´Ù. ÀçÀÔ¿øÀ» ÁÙÀÌ°í ¸¸¼º Áõ»ó °ü¸®¸¦ °³¼±Çϱâ À§ÇÑ º´¿øÀÇ ³ë·ÂÀº GES¸¦ °¡Ä¡ ÀÖ´Â Àå±â Ä¡·á Àü·«À¸·Î ´õ¿í ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¼¼°è GES ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

¼¼°è À§ Àü±â Àڱر⠽ÃÀåÀÇ ¼ºÀåÀº ÀÇ·á ¼ö¿ä, ±â¼ú ¹ßÀü, Ä¡·á ÃÖÀûÈ­¿¡ ±â¹ÝÇÑ ¸î °¡Áö ÇÙ½É ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, ƯÈ÷ ´ç´¢º´, ¿Ü°úÀû ÇÕº´Áõ, ½Å°æ°è ÁúȯÀ» ¾Î°í Àִ ȯÀÚ¿¡¼­ À§¸¶ºñ À¯º´·ü Áõ°¡´Â GESÀÇ ´ë»ó ȯÀÚ Ç®À» Á÷Á¢ÀûÀ¸·Î È®´ë½Ã۰í ÀÖ½À´Ï´Ù. µÑ°, Àå±âÀûÀÎ È¿°úÀÇ ÇѰè¿Í ½É°¢ÇÑ ºÎÀÛ¿ë°ú ÇÔ²² ±âÁ¸ ¾à¹° Ä¡·áÀÇ ½ÇÆÐ·Î ÀÎÇØ ÀÓ»óÀǵéÀÌ ±â±â ÁßÀç·Î ´«À» µ¹¸®°í ÀÖ½À´Ï´Ù. ¼Â°, ¼ÒÇüÈ­, ÇÁ·Î±×·¡¹Ö °¡´ÉÇÑ ÀÎÅÍÆäÀ̽º, ¹«¼± ¿¬°á µî ÇöÀç ÁøÇà ÁßÀÎ ±â¼ú °³¼±À¸·Î ÀÎÇØ GES ÀÓÇöõÆ®´Â ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô º¸´Ù È¿À²ÀûÀ̰í, ¸ÂÃãÇüÀ̸ç, »ç¿ëÇϱ⠽¬¿öÁö°í ÀÖ½À´Ï´Ù. ³Ý°, ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ º¸Çè»çÀÇ Áö¿ø°ú ÀÓ»ó Ä¡·á °¡À̵å¶óÀο¡ Æ÷ÇԵǸ鼭 ½Ã¼ú °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ºñ¸¸, ÁÖ±âÀû ±¸Åä ÁõÈıº µî GESÀÇ ÀûÀÀÁõ ¿Ü »ç¿ë ¹× º¸Á¶Àû »ç¿ëÀ» ޱ¸ÇÏ´Â ÀÓ»ó ¿¬±¸ÀÇ È®´ë·Î Ä¡·á Àü¸Á°ú ½ÃÀå ÀáÀç·ÂÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ GES´Â Æ´»õ ¼Ö·ç¼Ç¿¡¼­ ÷´Ü ¼ÒÈ­±â Ä¡·áÀÇ ÁÖ·ù·Î º¯¸ðÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(°íÁÖÆÄ À¯Çü, ÀúÁÖÆÄ À¯Çü), ¿ëµµ(À§¸¶ºñ ¿ëµµ, ºñ¸¸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ÃÖÁ¾ ¿ëµµ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 41»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gastric Electrical Stimulators Market to Reach US$352.2 Million by 2030

The global market for Gastric Electrical Stimulators estimated at US$258.1 Million in the year 2024, is expected to reach US$352.2 Million by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. High Frequency Type, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$225.7 Million by the end of the analysis period. Growth in the Low Frequency Type segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$70.3 Million While China is Forecast to Grow at 8.6% CAGR

The Gastric Electrical Stimulators market in the U.S. is estimated at US$70.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$71.2 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global "Gastric Electrical Stimulators" Market - Key Trends & Drivers Summarized

Why Are Gastric Electrical Stimulators Gaining Ground in Refractory Gastroparesis Management?

Gastric Electrical Stimulators (GES) have emerged as a crucial therapeutic option for patients suffering from chronic, drug-resistant gastroparesis-a condition characterized by delayed gastric emptying, often without mechanical obstruction. Affecting both diabetic and idiopathic populations, gastroparesis can severely impair quality of life through symptoms like nausea, vomiting, bloating, and abdominal pain. For patients unresponsive to dietary changes and pharmacological therapy, GES offers a minimally invasive, long-term intervention by delivering mild electrical pulses to the stomach’s smooth muscle to enhance motility and alleviate symptoms. Initially approved for humanitarian use, especially in the U.S. and Europe, GES has steadily gained clinical acceptance due to its safety profile and substantial symptom relief in select patient populations. With increasing awareness and diagnosis of gastroparesis, particularly among diabetics, the demand for GES implants is growing within gastroenterology and surgical practice worldwide.

How Are Technological Innovations Improving Device Performance and Patient Outcomes?

The evolution of GES devices is being driven by advancements in bioelectronic medicine, battery technology, and precision programming. Modern stimulators feature smaller, implantable pulse generators with extended battery life and programmable stimulation parameters, allowing physicians to tailor therapy to individual patient responses. Some systems now offer wireless telemetry, enabling non-invasive adjustments and remote monitoring. Improvements in lead design and placement techniques have also enhanced device efficacy and minimized procedural complications. Research is ongoing into closed-loop systems that can dynamically adjust stimulation in response to gastric feedback-offering the potential for more personalized, efficient symptom control. Furthermore, ongoing studies are exploring the use of GES for conditions beyond gastroparesis, such as obesity, functional dyspepsia, and chronic nausea syndromes, potentially widening the scope of clinical applications. These technical and therapeutic advancements are enhancing physician confidence in the procedure and expanding GES use in both academic and community hospital settings.

How Do Reimbursement, Clinical Guidelines, and Disease Burden Influence Market Expansion?

The adoption of gastric electrical stimulators is closely tied to healthcare reimbursement systems, evolving treatment protocols, and the rising prevalence of gastroparesis. In countries like the U.S., where Medicare and many private insurers now cover GES for specific indications, the barrier to access has been significantly reduced. Simultaneously, clinical guidelines are increasingly recognizing GES as a valid option for patients with refractory gastroparesis, reinforcing its role in treatment pathways. The rising global burden of diabetes-particularly type 2-has dramatically increased the incidence of diabetic gastroparesis, a key driver of GES implantation. Meanwhile, improvements in diagnostic tools such as gastric emptying scintigraphy are helping physicians identify suitable GES candidates earlier. In developing regions, limited access to advanced surgical interventions and cost constraints still pose challenges; however, growing investments in gastrointestinal health and rising awareness are beginning to open new regional markets. Hospital initiatives to reduce repeat admissions and improve chronic symptom management are further positioning GES as a valuable long-term care strategy.

What Key Drivers Are Accelerating Growth in the Global GES Market?

The growth in the global gastric electrical stimulators market is driven by several core factors rooted in medical need, technology progression, and treatment optimization. First, the rising prevalence of gastroparesis-especially in patients with diabetes, post-surgical complications, or neurological conditions-is directly expanding the eligible patient pool for GES. Second, failures of conventional pharmacotherapy, combined with limited long-term efficacy and significant side effects, are prompting clinicians to turn to device-based interventions. Third, ongoing technological refinements-such as miniaturization, programmable interfaces, and wireless connectivity-are making GES implants more efficient, customizable, and user-friendly for both patients and providers. Fourth, growing support from insurance providers and inclusion in clinical care guidelines are increasing procedural volume across North America, Europe, and parts of Asia-Pacific. Lastly, the expansion of clinical research exploring off-label and adjunctive uses of GES-such as for obesity and cyclic vomiting syndrome-is broadening its therapeutic landscape and market potential. These converging drivers are transforming GES from a niche solution into a mainstream component of advanced gastrointestinal care.

SCOPE OF STUDY:

The report analyzes the Gastric Electrical Stimulators market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (High Frequency Type, Low Frequency Type); Application (Gastroparesis Application, Obesity Application); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â